Emmaus, NIT sign Endari distribution agreement
Emmaus Life Sciences Announces Strategic Transaction
Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
Emmaus Life Sciences Reports 2024 Financial Results
Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
Emmaus Life Sciences Reports Improved Quarterly Financial Results
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
Leerink sees little impact to genetic medicines from Pfizer's Oxbryta withdrawal
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
Emmaus Life Sciences names Willis Lee as CEO
Emmaus Life Sciences appoints Willis Lee as CEO
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
Emmaus Life Sciences Reports 2023 Financial Results
Emmaus Life Sciences CEO Yutaka Niihara Reported Purchase of 53,800 Shares @ Avg Price of $1.49/Share in Form 4 Filing on Wednesday
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
